Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

5.3%

1 terminated/withdrawn out of 19 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

32%

6 trials in Phase 3/4

Results Transparency

86%

6 of 7 completed trials have results

Key Signals

3 recruiting6 with results

Enrollment Performance

Analytics

Phase 2

5(33.3%)

Phase 3

5(33.3%)

Phase 1

3(20.0%)

Phase 4

1(6.7%)

N/A

1(6.7%)

15Total

Phase 2(5)

Phase 3(5)

Phase 1(3)

Phase 4(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials

NCT03762850Phase 3Active Not Recruiting

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

Role: lead

NCT03493685Phase 3Completed

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

Role: lead

NCT06548022Not ApplicableCompleted

Rare Group Problem Management Plus

Role: collaborator

NCT07224776Phase 1Not Yet Recruiting

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Role: collaborator

NCT07219121Phase 4Recruiting

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

Role: lead

NCT05003986Phase 2Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Role: lead

NCT05856760Phase 2Completed

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

Role: lead

NCT05368038Enrolling By Invitation

ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program

Role: collaborator

NCT05630612Phase 2Active Not Recruiting

ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)

Role: collaborator

NCT01613118Phase 2Completed

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

Role: lead

NCT06431893Phase 3Enrolling By Invitation

A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

Role: lead

NCT06247085Phase 3Active Not Recruiting

A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment

Role: lead

NCT04663204Phase 2Active Not Recruiting

A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy

Role: collaborator

NCT03406611Phase 1Active Not Recruiting

Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)

Role: lead

NCT02998710Recruiting

Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)

Role: lead

NCT02638220Completed

Cerebrotendinous Xanthomatosis (CTX) Prevalence Study